Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.65 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100464 | 0.88 | SIGMAR1 (0.64) | SIGMAR1DRD4KMT2ADRD2DRD3 | |
| SCHEMBL4592089 | 0.86 | SIGMAR1 (0.68) | SIGMAR1DRD4KMT2AMCHR1TEAD1 | |
| SCHEMBL4592787 | 0.84 | SIGMAR1 (0.73) | SIGMAR1DRD4KMT2A | |
| SCHEMBL28361504 | 0.81 | SIGMAR1 (0.57) | SIGMAR1DRD4KMT2AMEN1TNIK | |
| SCHEMBL2636348 | 0.81 | KDM4E (0.60) | SIGMAR1TNIKKDM4EALDH1A1 | |
| SCHEMBL9592070 | 0.80 | MCHR1 (0.71) | SIGMAR1DRD4MCHR1 | |
| SCHEMBL5434322 | 0.78 | SIGMAR1 (0.58) | SIGMAR1DRD4DRD2MCHR1TEAD1 | |
| SCHEMBL4591750 | 0.78 | SIGMAR1 (0.58) | SIGMAR1DRD4DRD2MCHR1TEAD1 | |
| SCHEMBL5421451 | 0.78 | SIGMAR1 (0.58) | SIGMAR1DRD4DRD2MCHR1TEAD1 | |
| SCHEMBL4039839 | 0.78 | SIGMAR1 (0.80) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | SIGMAR1 59/4885DRD4 249/4885KMT2A 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.